Nikolay Bugaev, MD
Surgical Critical Care · Boston, MANPI 1124260187
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by AstraZeneca at 51.6% of the total. Reporting peaked in 2022 at $7,280 and has fallen 99.4% since, to $44 in 2025. Among surgical critical care clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 44 payments — averaging $385.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$9K
- Astrazeneca UK Limited$3K
- Cook Incorporated$3K
- CSL Behring$2K
- Activ Surgical, Inc.$625
- Aroa Biosurgery Incorporated$194
- plus $278 from 7 others
Across 38 payments — averaging $12,178 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$309K
- AstraZeneca$135K
- W. L. Gore & Associates, Inc.$15K
- New View Surgical, Inc.$3K
What the payments were for
- Consulting fees$9,52356%
- Speaking & faculty fees$3,58221%
- Travel & lodging$2,84417%
- Food & beverage$1,0136%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 13 | $8,761 |
| Astrazeneca UK Limited | 8 | $2,762 |
| Cook Incorporated | 1 | $2,532 |
| CSL Behring | 10 | $1,811 |
| Activ Surgical, Inc. | 2 | $625 |
| Aroa Biosurgery Incorporated | 2 | $194 |
| Johnson & Johnson | 2 | $72 |
| W. L. Gore & Associates, Inc. | 1 | $51 |
| Boston Scientific | 1 | $34 |
| Integra Lifesciences Corporation | 1 | $33 |
| TELA Bio, Inc. | 1 | $29 |
| Kerecis Limited | 1 | $29 |
| Davol Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANDEXXA$9,125
- Blue Rhino$2,532
- ActivSight$625
How this compares
$16,962 in reported general payments places this provider in the 90th percentile of 46 surgical critical care providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other surgical critical care in Boston
- Jeremy GovermanBoston$70K
- Jason BrockerBoston$33K
- William GormleyBoston$6K
- Noelle SaillantBoston$6K
- Vihas PatelBoston$5K
- Arfry Marcelino-TineoBoston$5K
- Adam HensleyBoston$5K
- Gentian KristoBoston$4K
- Adam AckermanBoston$4K
- Peter BurkeBoston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.